Novacyt (NCYT) Share Price, News & Analysis

Company Overview

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com

Key Stats

• Today's Range: 47.04 to 49.70
• 50-Day Range: 37.80 to 50
• 52-Week Range: 36 to 137
• Volume: 163,307 shs
• Average Volume: 177,709 shs
• Market Capitalization: £33.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NCYT Stock Analysis - Frequently Asked Questions

How have NCYT shares performed this year?

Novacyt's stock was trading at GBX 49.30 on January 1st, 2025. Since then, NCYT shares have decreased by 2.2% and is now trading at GBX 48.20.
View the best growth stocks for 2025 here.

How were Novacyt's earnings last quarter?

Novacyt S.A. (LON:NCYT) announced its quarterly earnings data on Wednesday, April, 30th. The company reported ($55.00) earnings per share for the quarter. Novacyt had a negative trailing twelve-month return on equity of 47.73% and a negative net margin of 203.06%.

How do I buy shares of Novacyt?

Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Mesa Air Group (MESA), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), Walmart (WMT) and boohoo group (BOO).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 5/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:NCYT
• CIK: N/A
• Web: www.novacyt.com
• Phone: 33 1 39 46 51 04
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (54.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£36.80 million
• Net Margins: -203.06%
• Pretax Margin: N/A
• Return on Equity: -47.73%
• Return on Assets: -27.98%

Debt

• Debt-to-Equity Ratio: 1.92
• Current Ratio: 4.04
• Quick Ratio: 4.46

Sales & Book Value

• Annual Sales: £18.12 million
• Price / Sales: 1.85
• Cash Flow: GBX 83.39 per share
• Price / Cash Flow: 0.58
• Book Value: GBX 99.62 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 69,096,990
• Free Float: N/A
• Market Cap: £33.44 million
• Optionable: Not Optionable
• Beta: -1.86